Riviciclib

Overview

Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase ( CDK ) inhibitor, which inhibits CDK9-cyclinT1 , CDK4-cyclin D1 , and CDK1-cyclinB with IC 50 s of 20 nM, 63 nM, and 79 nM, respectively. Riviciclib shows antitumor activity on cisplatin-resistant cells.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-16559A
• CAS No.: 920113-02-6
• Molecular Formula: C21H20ClNO5
• Molecular Weight: 401.84
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source